Managing Cardiac Rehabilitation Therapy

Managing Cardiac Rehabilitation Therapy

Structures Phase I-IV cardiac rehabilitation including risk stratification, exercise prescription using the Karvonen and Borg RPE methods, ECG telemetry monitoring parameters, progression criteria, and outcome documentation per AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation) guidelines.

Why This Skill Exists

Cardiac rehabilitation reduces cardiovascular mortality by 20-30% and is a CMS-covered benefit with specific documentation requirements. Exercise prescription for cardiac patients requires precise hemodynamic parameters, risk stratification, and continuous monitoring documentation. Incorrect exercise intensity, failure to document telemetry findings, or missing risk stratification renders programs non-compliant with AACVPR certification standards and creates medicolegal liability. Payers deny cardiac rehab claims when documentation fails to demonstrate medical necessity, supervised exercise need, and measurable outcomes. This skill produces documentation that satisfies clinical safety, payer, and accreditation requirements.

Checkpoint A — Intake Verification

Before initiating cardiac rehabilitation, confirm:

Required clinical questions:

• What is the qualifying cardiac diagnosis and event date (MI, CABG, PCI, valve surgery, stable angina, heart failure, heart transplant)?
• What is the current LVEF (left ventricular ejection fraction)?
• What are the current cardiac medications (beta-blockers, ACE inhibitors, antiarrhythmics, anticoagulants)?
• Has the patient had a recent exercise stress test (GXT) and what were the results?
• Are there exercise contraindications (unstable angina, decompensated HF, uncontrolled arrhythmia, acute pericarditis, aortic stenosis)?
• What is the patient's current functional capacity in METs?

Required documents:

• Cardiology consultation or discharge summary with diagnosis
• Echocardiogram report (LVEF, wall motion, valvular function)
• Graded exercise test (GXT) results if available (peak HR, peak METs, ischemic threshold, arrhythmia)
• Current medication list with dosing and timing
• Physician referral/order for cardiac rehabilitation
• CMS-required individualized treatment plan signed by referring physician

Step 1 — Perform Risk Stratification

Classify the patient using AACVPR risk categories:

Low risk:

• No significant LV dysfunction (LVEF ≥50%)
• No resting or exercise-induced complex arrhythmias
• No symptoms at ≥7 METs
• Uncomplicated MI, CABG, or PCI
• Appropriate hemodynamic response to exercise

Moderate risk:

• LVEF 40-49%
• Symptoms at 5-6.9 METs
• Signs/symptoms of ischemia at moderate workloads
• Failure to comply with exercise intensity

High risk:

• LVEF <40%
• Complex ventricular arrhythmias at rest or with exercise
• Symptoms at <5 METs
• Exercise-induced hypotension (SBP drop ≥10 mmHg)
• Survivor of cardiac arrest
• Heart failure (NYHA Class III-IV)
• Medical complication from MI

Risk category determines monitoring level: high-risk patients require continuous ECG telemetry for at least 12-18 sessions.

Step 2 — Prescribe Exercise Using FITT-VP Parameters

Frequency:

• Phase II (outpatient supervised): 3 sessions/week for 36 sessions (12 weeks) per CMS standard benefit
• Some patients qualify for additional 36 sessions (total 72) with documented medical necessity
• Phase III (maintenance): 3-5 days/week unsupervised

Intensity — calculate target heart rate (THR):

Karvonen method (preferred when maximal HR known from GXT):

• THR = [(HR max - HR rest) x intensity %] + HR rest
• Initial intensity: 40-60% of heart rate reserve (HRR)
• Progression target: 60-80% HRR
• If on beta-blocker: use HR from GXT while ON medication — do not use age-predicted max HR

Borg RPE method (when HR is unreliable):

• Use 6-20 Borg scale or 0-10 modified Borg scale
• Target: RPE 11-14 (6-20 scale) or 3-5 (0-10 scale) = "somewhat hard"
• RPE is required for patients on beta-blockers, pacemakers, or transplant recipients where HR response is blunted

MET method:

• Initial exercise at 40-60% of peak MET capacity from GXT
• If GXT not performed, estimate from functional status and use conservative starting point

Time:

• Aerobic conditioning: 20-60 minutes per session (including warm-up and cool-down)
• Warm-up: 5-10 minutes at low intensity
• Cool-down: 5-10 minutes with gradual reduction
• Initial sessions may be 15-20 minutes aerobic and progress to 30-45 minutes

Type:

• Treadmill walking, cycle ergometer, arm ergometer, recumbent stepper, Nu-Step
• Resistance training: begin after 2-4 weeks of aerobic conditioning if stable; 1-3 sets x 10-15 reps at 40-60% 1RM for major muscle groups

Step 3 — Monitor Hemodynamic Response During Exercise

Document before, during (peak), and after each session:

Required monitoring parameters:

• Heart rate (resting, peak exercise, recovery)
• Blood pressure (resting, peak exercise, post-cool-down)
• ECG rhythm (continuous telemetry for high/moderate risk; intermittent for low risk)
• RPE at peak exercise
• SpO2 if pulmonary comorbidity
• Symptoms: chest pain, dyspnea, dizziness, palpitations, diaphoresis

Exercise termination criteria (stop immediately):

• Chest pain or anginal equivalent
• SBP >250 mmHg or DBP >115 mmHg
• SBP drop >10 mmHg from baseline despite increasing workload
• New ST-segment changes (≥1mm depression or elevation)
• Sustained ventricular tachycardia or new arrhythmia with hemodynamic compromise
• SpO2 <88%
• Signs of poor perfusion (cyanosis, pallor, ataxia, confusion)
• Patient request to stop

Abnormal responses requiring physician notification:

• HR fails to increase with workload (chronotropic incompetence)
• Excessive HR response (>20 bpm above THR)
• New or changing arrhythmia pattern
• Anginal symptoms at lower workload than previous sessions
• Failure to recover to baseline HR within 5 minutes post-exercise

Step 4 — Progress Exercise Prescription Systematically

Progression protocol:

• Increase duration before intensity (add 2-5 minutes per session)
• Increase intensity by 5-10% HRR when patient tolerates current level for 2 consecutive sessions without adverse signs
• Add resistance training after 2-4 weeks if hemodynamically stable
• Progress from supervised equipment to functional activities (stair climbing, community walking)

Session documentation (per CMS requirements):

• Date and session number (e.g., "Session 12 of 36")
• Modalities performed with duration and intensity for each
• Hemodynamic response (HR, BP, RPE, rhythm at rest, peak, and recovery)
• Any adverse events or symptoms
• Modifications made and rationale
• Minutes of ECG monitoring

Step 5 — Measure Outcomes and Document Program Effectiveness

Required outcome measures:

• 6MWT: Baseline, mid-program (session 18), and discharge; MCID = 25-50m
• Peak MET capacity: From GXT if repeat test performed
• DASI (Duke Activity Status Index): Estimates functional capacity in METs from questionnaire
• PHQ-9: Depression screening at intake and discharge (depression common post-cardiac event)
• Body composition: Weight, BMI, waist circumference at intake and discharge
• Lipid panel, HbA1c, BP trends: Coordinate with cardiology for medical risk factor tracking

Program completion documentation:

• Total sessions attended out of authorized
• Adherence rate (>80% considered compliant)
• Functional capacity change (METs or 6MWT distance)
• Risk factor modification achieved
• Home exercise program prescribed with parameters
• Recommendations for Phase III maintenance or ongoing supervised exercise

Checkpoint B — Pre-Finalization Review

Before finalizing cardiac rehabilitation documentation:

• AACVPR risk stratification documented with supporting data
• Exercise prescription includes FITT-VP parameters with calculation method shown
• Telemetry monitoring level matches risk category
• Each session has hemodynamic data (HR, BP, RPE, rhythm) documented
• Exercise termination criteria are listed in the plan
• Progression criteria are objective and documented
• Outcome measures completed at baseline and discharge
• CMS-required individualized treatment plan signed by physician
• Session count tracked against authorized visits
• Discharge plan includes home exercise program and Phase III recommendations

Quality Audit

• Risk stratification uses AACVPR criteria with LVEF, GXT data, and symptom threshold
• THR calculated correctly using Karvonen or documented reason for RPE-only method
• Beta-blocker effect on HR accounted for in exercise prescription
• Every session has pre/peak/post HR, BP, and RPE documented
• ECG monitoring minutes documented per session
• Adverse events documented with response taken
• Outcome measures use validated instruments with MCID for comparison
• All [VERIFY] flags resolved or escalated to cardiologist
• Program documentation meets AACVPR certification standards
• Documentation supports CMS medical necessity requirements

Guidelines

• Cardiac rehab is a CMS-covered benefit for MI (within 12 months), CABG, PCI, stable angina, heart valve repair/replacement, heart/heart-lung transplant, and HFrEF (LVEF ≤35%, NYHA Class II-IV, on GDMT)
• Phase I (inpatient) begins within 24-48 hours post-event with progressive ambulation and education
• Phase II referral should occur before hospital discharge — delay reduces enrollment rates by >50%
• Never use age-predicted maximal HR (220-age) for exercise prescription in patients on beta-blockers
• RPE is the essential intensity monitor for transplant recipients (denervated heart does not respond normally to exercise)
• Resistance training is safe and effective after cardiac events when hemodynamically stable — do not omit
• Outcome documentation must include both physiological and patient-reported measures
• Depression is present in 20-30% of post-cardiac patients — screen and refer per AACVPR guidelines
• Emergency equipment (crash cart, defibrillator, emergency medications) must be immediately available per AACVPR standards
• Document patient education topics covered each session (nutrition, medication adherence, symptom recognition, stress management, smoking cessation)